Martha Q. Lacy is a Hematologist at Mayo Clinic, Rochester, Minnesota. She completed her MD from University of Colorado Medical Center and post-doctorate in Hematology/Oncology from Mayo Graduate School of Medicine, Mayo Clinic College of Medicine.

Dr. Lacy has been awarded as Woman of the year in 2015 by Leukemia and Lymphoma Society. She is primarily interested in myeloma, amyloidosis, Waldenstrom’s macroglobulinemia and other dysproteinemias and stem cell transplantation of these diseases.

As a member of Mayo Clinic’s myeloma, amyloidosis, dysproteinemia group, Martha Q. Lacy conducts research in developing new therapeutics for the treatment of plasma cell disorders.

Dr. Lacy’s clinical research centers on immunotherapy, stem cell transplant and novel agents to optimize treatment for multiple myeloma, amyloidosis, Waldenstrom’s macroglobulinemia and monoclonal gammopathy. She performs clinical trials and collaborates with scientists on translational research to improve outcomes for patients with these disorders.

Representative Publications:

Natural history of multiple myeloma with de novo del(17p)

Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma 

Share

Discuss in Social Wall

Twitter

Share to rareTeam

myBinder